ENTERA BIO LTD. Research and Development Expense
ENTERA BIO LTD. (ENTX) reported Research and Development Expense of $3.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- ENTERA BIO LTD. research and development expense for the quarter ending 2026-06-30 was $3.20M, a 110.59% increase year-over-year.
- ENTERA BIO LTD. research and development expense for the quarter ending 2026-03-31 was $2.25M, a 100.45% increase year-over-year.
- ENTERA BIO LTD. research and development expense for the quarter ending 2025-12-31 was $1.72M, a 43.05% increase year-over-year.
- ENTERA BIO LTD. research and development expense for the quarter ending 2025-09-30 was $1.64M, a 11.24% increase year-over-year.
- ENTERA BIO LTD. research and development expense for fiscal 2025 was $6.00M, a 33.45% increase from fiscal 2024.
- ENTERA BIO LTD. research and development expense for fiscal 2024 was $4.50M, a 0.24% decline from fiscal 2023.
- ENTERA BIO LTD. research and development expense for fiscal 2023 was $4.51M, a 22.88% decline from fiscal 2022.
- ENTERA BIO LTD. research and development expense for fiscal 2022 was $5.85M, a 13.63% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.20M 10-Q · filed 2026-08-07 | $5.45M 10-Q · filed 2026-08-07 | $7.17M derived: sum of 3 quarters · filed 2026-08-07 | $8.81M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $2.25M 10-Q · filed 2026-05-08 | $3.97M derived: sum of 2 quarters · filed 2026-05-08 | $5.61M derived: sum of 3 quarters · filed 2026-05-08 | $7.13M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $3.36M derived: sum of 2 quarters · filed 2026-03-27 | $4.88M derived: sum of 3 quarters · filed 2026-08-07 | $6.00M 10-K · filed 2026-03-27 |
| 2025-09-30 | $1.64M 10-Q · filed 2025-11-14 | $3.16M derived: sum of 2 quarters · filed 2026-08-07 | $4.29M 10-Q · filed 2025-11-14 | $5.49M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $1.52M 10-Q · filed 2026-08-07 | $2.64M 10-Q · filed 2026-08-07 | $3.84M derived: sum of 3 quarters · filed 2026-08-07 | $5.32M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $1.12M 10-Q · filed 2026-05-08 | $2.32M derived: sum of 2 quarters · filed 2026-05-08 | $3.80M derived: sum of 3 quarters · filed 2026-05-08 | $4.89M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $2.68M derived: sum of 2 quarters · filed 2026-03-27 | $3.76M derived: sum of 3 quarters · filed 2026-03-27 | $4.50M 10-K · filed 2026-03-27 |
| 2024-09-30 | $1.48M 10-Q · filed 2025-11-14 | $2.56M derived: sum of 2 quarters · filed 2025-11-14 | $3.30M 10-Q · filed 2025-11-14 | $4.30M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.09M 10-Q · filed 2025-08-08 | $1.82M 10-Q · filed 2025-08-08 | $2.82M derived: sum of 3 quarters · filed 2025-08-08 | $4.19M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $735.00K 10-Q · filed 2025-05-09 | $1.74M derived: sum of 2 quarters · filed 2025-05-09 | $3.10M derived: sum of 3 quarters · filed 2025-05-09 | $4.31M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $2.37M derived: sum of 2 quarters · filed 2025-03-28 | $3.58M derived: sum of 3 quarters · filed 2025-03-28 | $4.51M 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.37M 10-Q · filed 2024-11-08 | $2.58M derived: sum of 2 quarters · filed 2024-11-08 | $3.51M 10-Q · filed 2024-11-08 | $4.86M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $1.21M 10-Q · filed 2024-08-09 | $2.14M 10-Q · filed 2024-08-09 | $3.49M derived: sum of 3 quarters · filed 2024-08-09 | $4.90M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $931.00K 10-Q · filed 2024-05-10 | $2.28M derived: sum of 2 quarters · filed 2024-05-10 | $3.69M derived: sum of 3 quarters · filed 2024-05-10 | $5.09M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $2.76M derived: sum of 2 quarters · filed 2024-03-08 | $4.16M derived: sum of 3 quarters · filed 2024-03-08 | $5.85M 10-K · filed 2024-03-08 |
| 2022-09-30 | $1.41M 10-Q · filed 2023-11-14 | $2.81M derived: sum of 2 quarters · filed 2023-11-14 | $4.50M 10-Q · filed 2023-11-14 | $7.15M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.39M 10-Q · filed 2023-08-11 | $3.08M 10-Q · filed 2023-08-11 | $5.73M derived: sum of 3 quarters · filed 2023-08-11 | $7.50M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $1.69M 10-Q · filed 2023-05-05 | $4.34M derived: sum of 2 quarters · filed 2023-05-05 | $6.11M derived: sum of 3 quarters · filed 2023-05-05 | $7.34M derived: sum of 4 quarters · filed 2023-05-05 |
| 2021-12-31 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $4.42M derived: sum of 2 quarters · filed 2023-03-31 | $5.65M derived: sum of 3 quarters · filed 2023-03-31 | $6.77M 10-K · filed 2023-03-31 |
| 2021-09-30 | $1.77M 10-Q · filed 2022-11-10 | $3.00M derived: sum of 2 quarters · filed 2022-11-10 | $4.12M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $1.23M 10-Q · filed 2022-08-11 | $2.35M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $1.12M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $6.38M 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |